scholarly journals Parental Effect on the Humoral Immune Response to Escherichia coli and Newcastle Disease Virus in Young Broiler Chicks

1994 ◽  
Vol 73 (10) ◽  
pp. 1534-1541 ◽  
Author(s):  
G. LEITNER ◽  
M. GUTMAN ◽  
E.D. HELLER ◽  
N. YONASH ◽  
A. CAHANER
Keyword(s):  
Escherichia Coli ◽  
Immune Response ◽  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Humoral Immune Response ◽  
Broiler Chicks ◽  
Parental Effect ◽  
Humoral Immune

scholarly journals EVALUATION OF MATERNALLY DERIVED ANTIBODIES AGAINST NEWCASTLE DISEASE VIRUS AND ITS EFFECT ON VACCINATION IN BROILER CHICKS

2010 ◽  
Vol 7 (2) ◽  
pp. 296-302 ◽  
Author(s):  
MA Jalil ◽  
MA Samad ◽  
MT Islam
Keyword(s):  
Immune Response ◽  
Newcastle Disease ◽  
Humoral Immune Response ◽  
Broiler Chickens ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Broiler Chicks ◽  
Humoral Immune ◽  
Different Ages ◽  
Group B

The study was conducted to determine the persistence of maternally derived antibody (MDA) and its effects on protection against NDV in broiler chickens and to investigate the status of humoral immune response following vaccination with BCRDV® (F-strain, lentogenic) at different ages of broiler chickens during the period from August to October,  2008. A total of 90 day-old broiler chicks of Cobb 500 strain with the history of vaccination of parent stock against Newcastle disease (ND) was divided into three groups (A, B and C). Birds of group A (n = 35) were used for the study of protection ability of MDA against NDV, the birds of group B (n = 45) were used for the measurement of humoral immune response in chickens following vaccination at different ages and birds of group C (n = 10) were used for the determination of persistence of maternally derived antibody. The level of antibody titre against NDV was determined by HI test. The protective potentiality of MDA and vaccine was determined by the rate of survivability of the chickens following challenge infection. It was observed that the MDA titre in day-old chicks was higher and gradually declined at minimal level at day 28. The MDA titre of 128 or above protected the birds following challenge infection with virulent NDV. There were significant decrease in HI titres of chickens which were vaccinated once at day 1 and day 7, and could not withstand challenge infection with virulent NDV. Single vaccination with BCRDV® at day 14 triggered the production of antibody but could not provide complete protection to the birds. The birds which were boosted with the same vaccine 7 days and 21 days after primary vaccination produced better immune response. However, the birds which were vaccinated primarily at day 1 and boosted at day 7 could not withstand the challenge completely. Of the other regimens of twice vaccination, primary vaccination at day 7 and booster dosing at day 28 was found to be the best in terms of immune response and protection potentiality. Therefore, it may be concluded that (a) The MDA titre level of 128 or above is sufficient to protect broilers against challenge with virulent NDV,( b) Primary vaccination at day 7 followed by a booster dosing at day 28 may be followed for better immune response and protection against ND in broilers.DOI: 10.3329/bjvm.v7i2.5995Bangl. J. Vet. Med. (2009). 7(2) : 296 – 302

scholarly journals IMMUNE RESPONSE CAPABILITY OF `SHUVRA’ CHICKEN

2013 ◽  
Vol 10 (1-2) ◽  
pp. 1-7
Author(s):  
M. S. Sabrin ◽  
S. Saha ◽  
M. M. Amin
Keyword(s):  
Immune Response ◽  
Newcastle Disease Virus ◽  
Newcastle Disease ◽  
Humoral Immune Response ◽  
Passive Haemagglutination ◽  
Fowl Cholera ◽  
Humoral Immune ◽  
Unvaccinated Control ◽  
And Control ◽  
Observation Period

The study was carried out to determine the humoral immune response to Newcastle Disease Virus (NDV) and Bangladesh Agricultural University Fowl cholera (BAUFC) vaccines in Shuvra chicken, a newly develop chicken strain by BLRI (Bangladesh Livestock Research Institute). Ten Shuvra chickens were vaccinated with Baby Chick Ranikhet Disease Vaccine (BCRDV) at day 7 through intra ocular route (i/o) and with Ranikhet Disease Vaccine (RDV) at day 35 through intramuscular (i/m) route. Vaccine induced serum Haemagglunination Inhibition (HI) antibodies were measured by HI test. Two weeks after final immunization all vaccinated and control Shuvra chickens were challenged with virulent field isolates of  NDV where all the vaccinated birds survived without showing any typical signs of NDV during the period of ten days observation period and all the control chickens died.  Another 10 Shuvra were vaccinated twice with BAUFC vaccine through intramuscular route at day 42 and 70, and 10 Shuvra chickens were kept as unvaccinated control. This vaccine also induced significantly higher level of antibody titre as determined by Passive Haemagglutination (PHA) test. Vaccinated chickens showed significantly higher survival (80%) following challenge with virulent fowl cholera isolate and all the control birds died within 10 days of observation period. DOI: http://dx.doi.org/10.3329/bjvm.v10i1-2.15639Bangl. J. Vet. Med. (2012). 10 (1&2): 1-7

scholarly journals Optimization of Human Immunodeficiency Virus Gag Expression by Newcastle Disease Virus Vectors for the Induction of Potent Immune Responses

2008 ◽  
Vol 83 (2) ◽  
pp. 584-597 ◽  
Author(s):  
Elena Carnero ◽  
Wenjing Li ◽  
Antonio V. Borderia ◽  
Bruno Moltedo ◽  
Thomas Moran ◽  
...  
Keyword(s):  
Immune Response ◽  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Insertion Site ◽  
Gag Protein ◽  
Immunodeficiency Virus

ABSTRACT One attractive strategy for the development of a human immunodeficiency virus (HIV) vaccine is the use of viral vectors with a proven safety profile and an absence of preexisting immunity in humans, such as Newcastle disease virus (NDV). Several NDV vaccine vectors have been generated, and their immunogenicities have been investigated with different animal models. However, a systematic study to evaluate the optimal insertion site of the foreign antigens into NDV that results in enhanced immune responses specific to the antigen has not yet been conducted. In this article, we describe the ability of NDV expressing HIV Gag to generate a Gag-specific immune response in mice. We also have determined the optimal insertion site into the NDV genome by generating recombinant NDV-HIVGag viruses in which HIV gag was located at different transcriptional positions throughout the NDV viral genome. All recombinant viruses were viable, grew to similar titers in embryonated chicken eggs, and expressed Gag in a stable manner. Our in vivo experiments revealed that higher HIV Gag protein expression positively correlates with an enhanced CD8+ T-cell-mediated immune response and protective immunity against challenge with vaccinia virus expressing HIV Gag. We also inserted a codon-optimized version of HIV gag in the described best location, between the P and M genes. Virus expressing the codon-optimized version of HIV gag induced a higher expression of the protein and an enhanced immune response against HIV Gag in mice. These results indicate that strategies directed toward increasing antigen expression by NDV result in enhanced immunogenicity and vaccine efficacy.

Sign in / Sign up

Export Citation Format

Share Document